{"id":64977,"date":"2026-05-11T15:07:22","date_gmt":"2026-05-11T07:07:22","guid":{"rendered":"https:\/\/flcube.com\/?p=64977"},"modified":"2026-05-11T15:07:22","modified_gmt":"2026-05-11T07:07:22","slug":"gsk-partners-with-sino-biopharmaceuticals-cttq-subsidiary-to-commercialize-bepirovirsen-in-chinas-hepatitis-b-market","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64977","title":{"rendered":"GSK Partners with Sino Biopharmaceutical&#8217;s CTTQ Subsidiary to Commercialize Bepirovirsen in China&#8217;s Hepatitis B Market"},"content":{"rendered":"\n<p><strong>GlaxoSmithKline plc<\/strong> (GSK, <a href=\"https:\/\/www.google.com\/finance\/quote\/GSK:NYSE\">NYSE: GSK<\/a>) has announced a strategic licensing agreement with <strong>Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ)<\/strong>, a wholly-owned subsidiary of <strong>Sino Biopharmaceutical Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1177:HKG\">HKG: 1177<\/a>), for the <strong>commercialization of bepirovirsen<\/strong> in China\u2014the world&#8217;s largest hepatitis B market with approximately 70 million chronic carriers.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-structure-amp-operational-framework\">Partnership Structure &amp; Operational Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Party<\/th><th>Responsibilities<\/th><th>Revenue Recognition<\/th><\/tr><\/thead><tbody><tr><td><strong>CTTQ (Sino Bio Subsidiary)<\/strong><\/td><td>Import, distribution, hospital access, promotion, non-promotional activities<\/td><td><strong>100% of Chinese sales revenue<\/strong><\/td><\/tr><tr><td><strong>GlaxoSmithKline<\/strong><\/td><td>Regulatory filings, quality control, pharmacovigilance, global medical strategy<\/td><td>Supply revenue from product sales to CTTQ<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The <strong>5.5-year collaboration<\/strong> leverages CTTQ&#8217;s established commercial infrastructure\u2014reaching over 6,000 hospitals nationwide\u2014while maintaining GSK&#8217;s oversight of regulatory and quality standards. Under the agreement, Sino Biopharmaceutical will purchase bepirovirsen from GSK under predetermined supply terms, with all Chinese market sales recorded as Sino Bio revenue.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-regulatory-momentum\">Drug Profile &amp; Regulatory Momentum<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-therapeutic-innovation\">Therapeutic Innovation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Drug Class<\/strong>: Antisense oligonucleotide (ASO)<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Triple mechanism of action targeting multiple stages of hepatitis B virus replication<\/li>\n\n\n\n<li><strong>Indication<\/strong>: Chronic hepatitis B virus (HBV) infection<\/li>\n\n\n\n<li><strong>Development Stage<\/strong>: Late-stage clinical trials with robust regulatory support<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-chinese-regulatory-advantages\">Chinese Regulatory Advantages<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Breakthrough Therapy Designation (BTD)<\/strong>: Awarded by NMPA in August 2021<\/li>\n\n\n\n<li><strong>Priority Review Status<\/strong>: Subsequently granted by NMPA for accelerated approval pathway<\/li>\n\n\n\n<li><strong>Market Differentiation<\/strong>: One of few functional cure candidates with advanced regulatory status in China<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-amp-market-implications\">Strategic Rationale &amp; Market Implications<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-why-cttq\">Why CTTQ?<\/h3>\n\n\n\n<p>CTTQ brings distinct advantages to the partnership:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Hospital Penetration<\/strong>: Established relationships with tier-1 through tier-3 hospitals across all Chinese provinces<\/li>\n\n\n\n<li><strong>Commercial Scale<\/strong>: Sales force of 3,500+ representatives with hepatology expertise<\/li>\n\n\n\n<li><strong>Pricing Negotiation<\/strong>: Proven track record in NRDL negotiations and provincial tender processes<\/li>\n\n\n\n<li><strong>Manufacturing Synergies<\/strong>: Potential future local fill-finish capabilities reducing import dependency<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-market-opportunity-analysis\">Market Opportunity Analysis<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Addressable Population<\/strong>: 25-30 million eligible chronic HBV patients requiring functional cure approaches<\/li>\n\n\n\n<li><strong>Revenue Potential<\/strong>: Peak annual sales projection of \u00a52.5-3.5 billion ($350-490 million) by 2030<\/li>\n\n\n\n<li><strong>Competitive Positioning<\/strong>: First-mover advantage among ASO-based HBV therapies in China<\/li>\n\n\n\n<li><strong>Pricing Strategy<\/strong>: BTD status supports premium pricing above current nucleos(t)ide analogues<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-strategic-benefits-matrix\">Strategic Benefits Matrix<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For GSK<\/strong>: Rapid market access without direct commercial investment while maintaining quality control<\/li>\n\n\n\n<li><strong>For Sino Bio\/CTTQ<\/strong>: High-value innovative asset complementing existing hepatology portfolio<\/li>\n\n\n\n<li><strong>Risk Allocation<\/strong>: Clear operational boundaries minimize execution conflicts during critical launch phase<\/li>\n<\/ul>\n\n\n\n<p>This partnership exemplifies the sophisticated China-West biopharmaceutical collaboration model, where multinational innovators leverage specialized local subsidiaries&#8217; commercial excellence while retaining scientific governance.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding commercial performance, regulatory timelines, and market adoption for bepirovirsen in China. Actual results may differ due to competitive dynamics, pricing negotiations, clinical outcomes, and evolving reimbursement policies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051100176_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026051100176_c.\"><\/object><a id=\"wp-block-file--media-e352820b-00f0-47f0-b07e-39480507cad6\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051100176_c.pdf\">2026051100176_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051100176_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-e352820b-00f0-47f0-b07e-39480507cad6\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>GlaxoSmithKline plc (GSK, NYSE: GSK) has announced a strategic licensing agreement with Jiangsu Chia Tai&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[278,184,908,914,313],"class_list":["post-64977","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-glaxosmithkline","tag-gsk","tag-hkg-1177","tag-nyse-gsk","tag-sino-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GSK Partners with Sino Biopharmaceutical&#039;s CTTQ Subsidiary to Commercialize Bepirovirsen in China&#039;s Hepatitis B Market - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"GlaxoSmithKline plc (GSK, NYSE: GSK) has announced a strategic licensing agreement with Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a wholly-owned subsidiary of Sino Biopharmaceutical Ltd (HKG: 1177), for the commercialization of bepirovirsen in China\u2014the world&#039;s largest hepatitis B market with approximately 70 million chronic carriers.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64977\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK Partners with Sino Biopharmaceutical&#039;s CTTQ Subsidiary to Commercialize Bepirovirsen in China&#039;s Hepatitis B Market\" \/>\n<meta property=\"og:description\" content=\"GlaxoSmithKline plc (GSK, NYSE: GSK) has announced a strategic licensing agreement with Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a wholly-owned subsidiary of Sino Biopharmaceutical Ltd (HKG: 1177), for the commercialization of bepirovirsen in China\u2014the world&#039;s largest hepatitis B market with approximately 70 million chronic carriers.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64977\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-11T07:07:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64977#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64977\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GSK Partners with Sino Biopharmaceutical&#8217;s CTTQ Subsidiary to Commercialize Bepirovirsen in China&#8217;s Hepatitis B Market\",\"datePublished\":\"2026-05-11T07:07:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64977\"},\"wordCount\":439,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"GlaxoSmithKline\",\"GSK\",\"HKG: 1177\",\"NYSE: GSK\",\"Sino Biopharmaceutical\"],\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64977#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64977\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64977\",\"name\":\"GSK Partners with Sino Biopharmaceutical's CTTQ Subsidiary to Commercialize Bepirovirsen in China's Hepatitis B Market - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-11T07:07:22+00:00\",\"description\":\"GlaxoSmithKline plc (GSK, NYSE: GSK) has announced a strategic licensing agreement with Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a wholly-owned subsidiary of Sino Biopharmaceutical Ltd (HKG: 1177), for the commercialization of bepirovirsen in China\u2014the world's largest hepatitis B market with approximately 70 million chronic carriers.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64977#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64977\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64977#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK Partners with Sino Biopharmaceutical&#8217;s CTTQ Subsidiary to Commercialize Bepirovirsen in China&#8217;s Hepatitis B Market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK Partners with Sino Biopharmaceutical's CTTQ Subsidiary to Commercialize Bepirovirsen in China's Hepatitis B Market - Insight, China&#039;s Pharmaceutical Industry","description":"GlaxoSmithKline plc (GSK, NYSE: GSK) has announced a strategic licensing agreement with Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a wholly-owned subsidiary of Sino Biopharmaceutical Ltd (HKG: 1177), for the commercialization of bepirovirsen in China\u2014the world's largest hepatitis B market with approximately 70 million chronic carriers.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64977","og_locale":"en_US","og_type":"article","og_title":"GSK Partners with Sino Biopharmaceutical's CTTQ Subsidiary to Commercialize Bepirovirsen in China's Hepatitis B Market","og_description":"GlaxoSmithKline plc (GSK, NYSE: GSK) has announced a strategic licensing agreement with Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a wholly-owned subsidiary of Sino Biopharmaceutical Ltd (HKG: 1177), for the commercialization of bepirovirsen in China\u2014the world's largest hepatitis B market with approximately 70 million chronic carriers.","og_url":"https:\/\/flcube.com\/?p=64977","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-11T07:07:22+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64977#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64977"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GSK Partners with Sino Biopharmaceutical&#8217;s CTTQ Subsidiary to Commercialize Bepirovirsen in China&#8217;s Hepatitis B Market","datePublished":"2026-05-11T07:07:22+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64977"},"wordCount":439,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["GlaxoSmithKline","GSK","HKG: 1177","NYSE: GSK","Sino Biopharmaceutical"],"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64977#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64977","url":"https:\/\/flcube.com\/?p=64977","name":"GSK Partners with Sino Biopharmaceutical's CTTQ Subsidiary to Commercialize Bepirovirsen in China's Hepatitis B Market - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-11T07:07:22+00:00","description":"GlaxoSmithKline plc (GSK, NYSE: GSK) has announced a strategic licensing agreement with Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a wholly-owned subsidiary of Sino Biopharmaceutical Ltd (HKG: 1177), for the commercialization of bepirovirsen in China\u2014the world's largest hepatitis B market with approximately 70 million chronic carriers.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64977#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64977"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64977#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GSK Partners with Sino Biopharmaceutical&#8217;s CTTQ Subsidiary to Commercialize Bepirovirsen in China&#8217;s Hepatitis B Market"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64977","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64977"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64977\/revisions"}],"predecessor-version":[{"id":64985,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64977\/revisions\/64985"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64977"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64977"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64977"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}